Fig. 4

AZD1775 sensitizes ALL blasts to the nucleoside analog cytarabine and enhances apoptotic cell death. A Representative dose–response matrix analyses showing cell inhibition (top) and synergistic landscape (bottom) across diverse AZD1775-AraC dose combinations after 96 h in a NALM6 TP53 isogenic model. Grey dashed boxes indicate the most synergistic area. B Pairwise combinations of AZD1775 with conventional ALL chemotherapy agents. Synergistic effects were quantified by most synergistic area scores as in A. Error bars indicate mean ± SD of three independent experiments in technical triplicate. C Evaluation of apoptotic by Annexin-V staining with flow cytometry in a NALM6 TP53 isogenic model treated with AZD1775 (200 nM), AraC (15 nM), or their combination for 24 and 48 h. Error bars indicate mean ± SD of three independent experiments